Bempedoic acid

It's a modest lever on its own, lowering LDL by around 15-25%, less than a statin, and it's often combined with

Ezetimibe to roughly double that. But it's one of the few non-statin oral drugs with hard outcome data: in statin-intolerant people it cuts the risk of heart attacks and the need for stent or bypass procedures. You won't feel anything taking it, the entire effect is on your bloodwork and your long-term risk. It's sold as Nexletol on its own, and as Nexlizet in a fixed-dose combination with ezetimibe.

Deep-dive

Bempedoic acid is a prodrug, meaning it's inactive when you swallow it and has to be switched on by an enzyme. That activating enzyme, ACSVL1, exists in the liver but essentially not in skeletal muscle. This is the whole design trick. Once activated in the liver, it inhibits an enzyme called ATP citrate lyase (ACL), which sits in the cholesterol production line two steps above HMG-CoA reductase, the enzyme statins block. Choke the line at either point and the liver ends up with less cholesterol inside its cells, so it puts more LDL receptors on its surface to pull cholesterol in from the blood. More receptors, more LDL cleared, lower LDL in your bloodstream. It reaches the same endpoint as a statin by a parallel route, which is why it stacks cleanly on top of one. Because muscle cells can't activate the prodrug, the drug never really becomes active there, and that's the mechanistic reason muscle symptoms are rare.

How much it actually lowers LDL. This is where expectations need to be set honestly. On top of a statin, bempedoic acid lowers LDL by around 18%. In statin-intolerant people taking little or no statin, it's closer to 21%. Combined with ezetimibe in a single tablet, the two together produce roughly a 38% reduction. For comparison, a high-intensity statin alone does 50% or more, and a PCSK9 inhibitor does 50-60%. So bempedoic acid is a smaller lever. Its value isn't the size of the drop, it's that it's an oral drug that works in people who've run out of other oral options.

It also lowers inflammation. Alongside LDL, bempedoic acid reduces high-sensitivity CRP, a marker of vascular inflammation, by around 20-22%. This is unusual, ezetimibe and PCSK9 inhibitors don't meaningfully touch hsCRP, while statins do. Whether the CRP drop contributes independently to the outcome benefit or is just riding along with the LDL reduction isn't settled, but it's a real and somewhat distinctive feature of the drug.

Does it actually prevent events? This is the question that matters, because plenty of drugs move a lab number without changing what happens to you. The CLEAR Outcomes trial answered it. It randomized 13,970 people who were statin-intolerant and either had cardiovascular disease or were at high risk for it, to bempedoic acid 180 mg daily or placebo, and followed them a median of about 3.4 years. Baseline LDL averaged 139 mg/dL. Bempedoic acid cut the primary endpoint, a composite of cardiovascular death, heart attack, stroke, and coronary revascularization, by 13%. Looking at the harder three-part endpoint of cardiovascular death, heart attack and stroke, the reduction was 15%. Heart attacks specifically dropped by 23% and revascularization procedures by 19%. The number needed to treat to prevent one primary event was 43, which cardiologists consider a large effect for a lipid drug.

The honest caveat on mortality. Unlike

Alirocumab, bempedoic acid did not show a statistically significant reduction in death from any cause or in cardiovascular death in CLEAR Outcomes. The benefit was real but concentrated in non-fatal events and procedures. That's a meaningful distinction if you're comparing it head to head with other lipid drugs, it moves events, it hasn't been shown to move mortality.

Primary prevention. One of the more striking findings came from the primary prevention subgroup, the 4,206 people who had high risk but had never actually had a heart attack or stroke. In that group the reduction in major events was 30%, larger than in the trial as a whole. Mean age was 68, 59% were women, and 66% had diabetes. This is notable because most outcome data for newer lipid drugs comes from people who already have established disease, and here the drug looked at least as good, arguably better, in people trying to avoid a first event.

Women. CLEAR Outcomes enrolled 48% women, 6,740 of them, the highest proportion of any contemporary lipid-lowering outcomes trial, which makes the female data here unusually solid rather than an afterthought. A prespecified analysis by sex found bempedoic acid lowered cardiovascular risk comparably in women and men, with no meaningful difference in relative benefit and no difference in side effects or lab changes. At baseline the women in the trial were older, had more diabetes and more peripheral and cerebrovascular disease, and were less likely to already be on lipid-lowering therapy, which mirrors the real-world pattern of women being undertreated for cholesterol. There's also a pooled analysis of four phase 3 trials suggesting women may get a somewhat larger LDL reduction than men, a placebo-corrected drop of about 21% versus 17% in the on-statin group, with bigger reductions in non-HDL cholesterol and ApoB as well. The practical read: it works at least as well in women, the dose is the same, and it's a genuinely useful option for the large number of women who report statin intolerance. It is not used in pregnancy or breastfeeding, lipid-lowering drugs are generally paused during this period and there's no adequate human safety data.

Older adults. The primary prevention group skewed older (mean 68) and still showed the largest benefit, and the overall trial included people up to 85. Because bempedoic acid doesn't carry the muscle-symptom burden of high-intensity statins, it's a practical way to lower LDL in older people without pushing statin doses they may not tolerate. No dose adjustment for age. The one thing to watch in older adults is the tendon and uric acid signals below, since both gout and tendon problems are already more common with age.

Diabetes and glucose. Statins carry a small, real signal for new-onset diabetes, so this was checked. A prespecified analysis found bempedoic acid did not increase new-onset diabetes and did not worsen blood sugar control, and people who already had diabetes got a similar relative benefit. If anything this is a point in its favor versus statins for people who are prediabetic or worried about glucose.

Limitations of the evidence. The outcome trial studied one specific population, statin-intolerant people, so the hard endpoint data is strongest there. "Statin intolerance" is also a somewhat soft entry criterion, it depends on patient report, and some trial participants might have tolerated a statin under other circumstances. The trial was industry-funded, normal at this stage but worth noting. There's no head-to-head outcome trial against ezetimibe or against a PCSK9 inhibitor, so the comparison between non-statin options is indirect. And as covered, the mortality benefit seen with some other lipid drugs was not demonstrated here.

Dosage:

• Standard dose is 180 mg once daily, as a single tablet. There's no titration, you don't work up to it, and the dose is the same for everyone regardless of sex, age, or body weight

• Take it with or without food, at whatever time of day you'll remember consistently. Unlike some statins it doesn't need to be timed to the evening

• It's almost always an add-on, not a replacement. If you can tolerate any statin dose at all, keep it going, bempedoic acid stacks on top. The exception is genuine, complete statin intolerance, where it's used without one

• For a bigger LDL drop, it's commonly paired with
  
  Ezetimibe, either as two separate pills or as the fixed-dose combination tablet (180 mg bempedoic acid / 10 mg ezetimibe). The combination roughly doubles the LDL reduction and is the more practical choice if you need to get LDL down substantially

• Statin dose caps apply when combining. Bempedoic acid raises blood levels of simvastatin and pravastatin, so doses above 20 mg simvastatin or 40 mg pravastatin should be avoided alongside it. Other statins like atorvastatin and rosuvastatin don't have this restriction. See the statins page for context

• Give it about 8-12 weeks before checking a lipid panel. The LDL effect appears within the first few weeks but you want a stable reading before deciding whether you need to add ezetimibe or another agent

• This is a long-term drug. LDL drifts back to baseline within weeks of stopping, the same as with statins, so it's only worth taking if you intend to stay on it

• Women take the same dose as men. Not used in pregnancy or breastfeeding

Here's what you can expect:

Side effects & risks:

• It's generally well tolerated, and crucially it does not cause the muscle symptoms that drive people off statins. In the outcome trial, muscle-related complaints were no higher than placebo, and in some analyses slightly lower

• Raised uric acid and gout are the most distinctive side effect. Bempedoic acid pushes uric acid up, and gout occurred more often than on placebo (roughly 3% versus 2%). It can show up within the first few weeks. If you have a history of gout, this is the main thing to flag with your prescriber

• Tendon rupture is an uncommon but real signal. Rates were low (around 0.5% in the hypercholesterolemia trials, about 1.2% versus 0.9% in the outcome trial) but the drug carries a specific warning for it. Tendon problems tend to affect the shoulder, bicep, or Achilles. If you get sudden tendon pain or swelling, stop and get it checked. Risk is higher in older people and with concurrent fluoroquinolone antibiotics or corticosteroids

• Small rise in creatinine and a modest increase in reported kidney-function issues. This is usually a measured change rather than a sign of real kidney damage, but it's worth a baseline so a later reading isn't misread

• Cholelithiasis (gallstones) occurred slightly more often than on placebo (around 2-2.5% versus 1-1.5%)

• Small increases in liver enzymes can occur, generally mild. A baseline is standard before starting

• Hematologic changes: phase 3 trials showed bempedoic acid can modestly raise platelet count and homocysteine and slightly lower hemoglobin and hematocrit. These are mostly subclinical and didn't translate into obvious problems in the trials, but they've been flagged by researchers as worth keeping an eye on given the drug is taken long-term

• Allergic reactions are uncommon but possible, ranging from rash and hives to, rarely, angioedema or anaphylaxis. Don't use it again if you've had a serious reaction

• Drug interactions are limited but real: the simvastatin and pravastatin dose caps above, and bempedoic acid can interact with fibrates. It doesn't have the broad CYP450 entanglements some drugs do

• Pregnancy and breastfeeding: not used. No adequate human data, and lipid-lowering therapy is generally paused during this period

• Severe kidney or liver impairment: less well characterized, since these patients were largely excluded from the major trials